DK0809635T3 - Alfa-Substituerede hydrazider med calpain-hæmmende virkning - Google Patents

Alfa-Substituerede hydrazider med calpain-hæmmende virkning

Info

Publication number
DK0809635T3
DK0809635T3 DK96903726T DK96903726T DK0809635T3 DK 0809635 T3 DK0809635 T3 DK 0809635T3 DK 96903726 T DK96903726 T DK 96903726T DK 96903726 T DK96903726 T DK 96903726T DK 0809635 T3 DK0809635 T3 DK 0809635T3
Authority
DK
Denmark
Prior art keywords
calpain
alpha
inhibitory effect
processes
substituted hydrazides
Prior art date
Application number
DK96903726T
Other languages
English (en)
Inventor
Kevin Ka-Wang Wang
Po-Wai Yuen
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Application granted granted Critical
Publication of DK0809635T3 publication Critical patent/DK0809635T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK96903726T 1995-02-16 1996-01-24 Alfa-Substituerede hydrazider med calpain-hæmmende virkning DK0809635T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/389,525 US5679680A (en) 1995-02-16 1995-02-16 α-substituted hydrazides having calpain inhibitory activity
PCT/US1996/001140 WO1996025403A1 (en) 1995-02-16 1996-01-24 α-SUBSTITUTED HYDRAZIDES HAVING CALPAIN INHIBITORY ACTIVITY

Publications (1)

Publication Number Publication Date
DK0809635T3 true DK0809635T3 (da) 2002-01-07

Family

ID=23538626

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96903726T DK0809635T3 (da) 1995-02-16 1996-01-24 Alfa-Substituerede hydrazider med calpain-hæmmende virkning

Country Status (11)

Country Link
US (1) US5679680A (da)
EP (1) EP0809635B1 (da)
JP (1) JPH11500124A (da)
AT (1) ATE206408T1 (da)
AU (1) AU4771396A (da)
CA (1) CA2208073A1 (da)
DE (1) DE69615664T2 (da)
DK (1) DK0809635T3 (da)
ES (1) ES2165487T3 (da)
PT (1) PT809635E (da)
WO (1) WO1996025403A1 (da)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002010768A2 (en) * 2000-07-31 2002-02-07 The Regents Of The University Of California Model for alzheimer's disease and other neurodegenerative diseases
WO2002088303A2 (en) 2001-04-03 2002-11-07 Bristol-Myers Squibb Company Polynucleotide encoding a novel cysteine protease of the calpain superfamily, can-12, and variants thereof
JP2008509212A (ja) * 2004-08-09 2008-03-27 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー 中枢神経系障害の治療のための新規なキノキサリノンノルエピネフリン再吸収阻害剤
DE102007050673A1 (de) 2007-10-19 2009-04-23 Friedrich-Schiller-Universität Jena Neue Hexaaza-acene und Verfahren zu ihrer Herstellung

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA735766B (en) * 1973-08-22 1975-04-30 Merck & Co Inc Ethylene generation
US4124718A (en) * 1977-01-21 1978-11-07 Merrell Toraude Et Compagnie Enhancing zinc serum and tissue levels
US4169149A (en) * 1977-01-21 1979-09-25 Giroux Eugene L Use of α-mercapto-β-arylacrylic acid derivatives in heavy metal poisoning
US4347255A (en) * 1980-04-17 1982-08-31 Richardson-Merrell Inc. Snake bite therapy
US4400382A (en) * 1980-05-09 1983-08-23 Usv Pharmaceutical Corporation Thiazoloquinoxalin-1,4-diones for treating allergy
US4354027A (en) * 1980-05-19 1982-10-12 Usv Pharmaceutical Corporation Triazoloquinoxalin-4-ones
US4439443A (en) * 1981-08-07 1984-03-27 Richardson-Merrell Inc. Snake bite therapy
JPS60166641A (ja) * 1984-02-10 1985-08-29 Teijin Ltd α，β−不飽和カルボン酸類
US4999436A (en) * 1987-09-22 1991-03-12 Merck & Co., Inc. Aryl-substituted thiophene 3-ols, derivatives and analogs useful as lipoxgenase inhibitors
DD282006A5 (de) * 1988-09-13 1990-08-29 Akad Wissenschaften Ddr Herstellungsverfahren fuer 5-nitrofur-2-yl-olefine
DK162491D0 (da) * 1991-09-20 1991-09-20 Novo Nordisk As Heterocycliske forbindelser, deres fremstilling og farmaceutiske praeparater indeholdende forbindelserne
CA2111930A1 (en) * 1992-12-25 1994-06-26 Ryoichi Ando Aminoketone derivatives
DK0603769T3 (da) * 1992-12-25 1999-06-14 Mitsubishi Chem Corp Alfa-aminoketonderivater
DK31093D0 (da) * 1993-03-19 1993-03-19 Novo Nordisk As
JPH07193474A (ja) * 1993-12-27 1995-07-28 Sharp Corp 波形成形回路

Also Published As

Publication number Publication date
WO1996025403A1 (en) 1996-08-22
DE69615664T2 (de) 2002-08-08
EP0809635A1 (en) 1997-12-03
PT809635E (pt) 2002-03-28
JPH11500124A (ja) 1999-01-06
DE69615664D1 (de) 2001-11-08
US5679680A (en) 1997-10-21
CA2208073A1 (en) 1996-08-22
ES2165487T3 (es) 2002-03-16
AU4771396A (en) 1996-09-04
EP0809635B1 (en) 2001-10-04
ATE206408T1 (de) 2001-10-15

Similar Documents

Publication Publication Date Title
RU93058531A (ru) Фторалкоксибензиламинные производные азотсодержащих гетероциклов, фармацевтическая композиция, способ лечения
DE69434431D1 (de) Methoden zur behandlung von muskelerkrankungen und muskelstörungen
UA27911C2 (uk) Засіб для лікування або запобігання фізіологічних розладів, які викликані надлишком тахікініну
DE59608740D1 (de) Cyclische und heterocyclische n-substituierte alpha-iminohydroxam- und carbonsäuren
DE60022050T2 (de) Metabotrope glutamatrezeptorantagonisten zur behandlung von krankheiten des zentralen nervensystems
DE60027431D1 (de) Verwendung von p38 MAPK Inhibitoren in der Behandlung von Augenkrankheiten
DE60142236D1 (de) Substituierte 5-alkinyl-pyrimidine mit neurotropher wirkung
IS4073A (is) Nýtt fjölvirknislyf gegn aukningu mótstöðu
TR200201094T2 (tr) Farmasötik maddeler olarak bisiklik amino asitler
DE60312736D1 (de) 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems
ATE381533T1 (de) Pharmazeutisch wirksame verbindungen und methoden zu ihrer anwendung
ES2164109T3 (es) Derivados de n-(3-piperidinilcarbonil)-beta-alanina como antagonistas de paf.
TR200101149T2 (tr) Dış retina bozukluklarının tedavisi.
DK0809635T3 (da) Alfa-Substituerede hydrazider med calpain-hæmmende virkning
MXPA05004273A (es) Derivados de fenilalquil y piridilalquil piperazina.
ATE126205T1 (de) Disubstituierte arylverbindungen welche eine selektive leukotrien-b4 antagonistische aktivität aufweisen.
DE69917074D1 (de) Optisch aktives pyridyl-4h-1,2,4-oxadiazinderivat und seine verwendung zur behandlung von gefässkrankheiten
ATE425967T1 (de) Piperazin und piperadin-derivate fur die behandlung von neurologischen krankheiten
ATE214605T1 (de) Verwendung von eliprodil zur herstellung eines arzneimittels zur behandlung von ischämischen störungen der retina oder des sehnervs
ATE285773T1 (de) Pharmazeutische zusammensetzungen zur behandlung von neurologischen krankheiten
CA2534303A1 (en) Aryl, heteroaromatic and bicyclic aryl nitrone compounds, prodrugs and pharmaceutical compositions of the same to treat human disorders
HUP9701150A2 (hu) Azaxantonszármazékok alkalmazása látászavarok megelőzésére és kezelésére szolgáló gyógyszerkészítmények előállítására
DE69626916D1 (de) Sertralin zur Behandlung von Post-Myocard-Infarkt-Patienten
DE60306503D1 (de) Statin-therapie zur verbesserung der aufrechterhaltung der kognitiven funktion
NO984651L (no) Anvendelse av benzonaftalenderivater for fremstilling av medikamenter for behandling av sykdommer i sentralnervesystemet